<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399475</url>
  </required_header>
  <id_info>
    <org_study_id>821564</org_study_id>
    <secondary_id>K24AG042765-01A1</secondary_id>
    <nct_id>NCT02399475</nct_id>
  </id_info>
  <brief_title>Mechanistic Study of Subclinical Hypothyroidism In the Elderly</brief_title>
  <official_title>The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subclinical hypothyroidism, defined as an elevated TSH in the setting of normal thyroid&#xD;
      hormone levels, is a common diagnosis in the elderly. The purpose of this study is to examine&#xD;
      the hypothalamic-pituitary-thyroid axis in men and women aged 70 years and older with&#xD;
      persistent subclinical hypothyroidism. To evaluate the mechanism behind this condition,&#xD;
      participants will undergo thyrotropin releasing hormone stimulation testing at 3 visits:&#xD;
      baseline and while taking two different thyroid hormone preparations, levothyroxine and&#xD;
      liothyronine. The investigators will also assess physiologic responses to these two different&#xD;
      thyroid hormone medications to help us understand how the thyroid works in advanced age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSH Area Under the Curve</measure>
    <time_frame>0, 5, 10, 15, 20, 30, and 60 min post TRH</time_frame>
    <description>TSH area under the curve within 60 minutes of TRH stimulation when TSH is at goal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TSH Max</measure>
    <time_frame>Between 0 and 180 min after TRH stimulation</time_frame>
    <description>The maximum concentration of TSH after TRH stimulation when TSH is at goal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Free T4 Level</measure>
    <time_frame>An average of 7 months after initiating therapy</time_frame>
    <description>Free thyroxine level when TSH level is at goal on therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total T3 Level</measure>
    <time_frame>An average of 7 months</time_frame>
    <description>Total triiodothyronine level when TSH is at goal on therapy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Subclinical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxine First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liothyronine First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L</description>
    <arm_group_label>Levothyroxine First</arm_group_label>
    <arm_group_label>Liothyronine First</arm_group_label>
    <other_name>Synthroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liothyronine</intervention_name>
    <description>Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L</description>
    <arm_group_label>Levothyroxine First</arm_group_label>
    <arm_group_label>Liothyronine First</arm_group_label>
    <other_name>Cytomel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thyrotropin-Releasing Hormone</intervention_name>
    <description>200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).</description>
    <arm_group_label>Levothyroxine First</arm_group_label>
    <arm_group_label>Liothyronine First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. men and women aged 70 and older&#xD;
&#xD;
          2. TSH between 4.5 and 19.9 mU/L as an outpatient&#xD;
&#xD;
          3. ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Laboratory Tests:&#xD;
&#xD;
          1. TSH &lt;4.5 mU/L or &gt;20 mU/L on repeat testing at least four weeks later or free T4 level&#xD;
             outside the reference range&#xD;
&#xD;
          2. thyroid peroxidase (TPO) antibody positive&#xD;
&#xD;
          3. abnormal liver function tests (LFTs &gt;3 x upper limit of normal)&#xD;
&#xD;
          4. hemoglobin &lt;11 g/dL&#xD;
&#xD;
        Surgeries or Procedures:&#xD;
&#xD;
          1. thyroid surgery&#xD;
&#xD;
          2. pituitary surgery&#xD;
&#xD;
          3. bariatric surgery&#xD;
&#xD;
          4. bowel resection involving the jejunum and upper ileum&#xD;
&#xD;
          5. radioactive iodine therapy&#xD;
&#xD;
          6. radiation treatments to head or neck&#xD;
&#xD;
        Medical Conditions:&#xD;
&#xD;
          1. diagnosis of pituitary disease&#xD;
&#xD;
          2. diagnosis of amyloidosis, sarcoidosis, hemochromatosis&#xD;
&#xD;
          3. diagnosis of adrenal insufficiency&#xD;
&#xD;
          4. obesity with BMI &gt; 35 mg/kg2&#xD;
&#xD;
          5. history of stroke&#xD;
&#xD;
          6. chronic or ongoing angina, Class II or higher congestive heart failure, or&#xD;
             uncontrolled hypertension with current blood pressure greater than 160/100&#xD;
&#xD;
          7. diabetes mellitus with hemoglobin A1C level greater than 8.0% in the past six months&#xD;
&#xD;
          8. celiac sprue, Crohn's disease, ulcerative colitis, Zollinger-Ellison syndrome&#xD;
&#xD;
          9. renal insufficiency with calculated glomerular filtration rate &lt;45 cc/min&#xD;
&#xD;
         10. cognitive impairment with Mini Mental State Exam[30] &lt;24/30&#xD;
&#xD;
         11. history of any seizures&#xD;
&#xD;
         12. unstable medical or psychological condition in the judgment of the principal&#xD;
             investigator&#xD;
&#xD;
        Medications:&#xD;
&#xD;
          1. thyroid hormone preparations&#xD;
&#xD;
          2. antithyroid drugs&#xD;
&#xD;
          3. medications that interfere with the absorption or metabolism of thyroid hormone&#xD;
&#xD;
          4. medications that interfere with the TRH stimulation test&#xD;
&#xD;
          5. proton pump inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne R Cappola, MD, ScM</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <results_first_submitted>January 21, 2021</results_first_submitted>
  <results_first_submitted_qc>February 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2021</results_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levothyroxine</keyword>
  <keyword>Liothyronine</keyword>
  <keyword>Thyrotropin Releasing Hormone</keyword>
  <keyword>Aging</keyword>
  <keyword>Hypothyroidism</keyword>
  <keyword>Thyroid diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02399475/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levothyroxine First</title>
          <description>Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine&#xD;
Levothyroxine: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Liothyronine: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Thyrotropin-Releasing Hormone: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).</description>
        </group>
        <group group_id="P2">
          <title>Liothyronine First</title>
          <description>Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine&#xD;
Levothyroxine: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Liothyronine: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Thyrotropin-Releasing Hormone: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levothyroxine First</title>
          <description>Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine&#xD;
Levothyroxine: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Liothyronine: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Thyrotropin-Releasing Hormone: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).</description>
        </group>
        <group group_id="B2">
          <title>Liothyronine First</title>
          <description>Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine&#xD;
Levothyroxine: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Liothyronine: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L&#xD;
Thyrotropin-Releasing Hormone: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77" spread="5"/>
                    <measurement group_id="B2" value="77" spread="4"/>
                    <measurement group_id="B3" value="77" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TSH Area Under the Curve</title>
        <description>TSH area under the curve within 60 minutes of TRH stimulation when TSH is at goal</description>
        <time_frame>0, 5, 10, 15, 20, 30, and 60 min post TRH</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine</title>
            <description>While taking levothyroxine</description>
          </group>
          <group group_id="O2">
            <title>Liothyronine</title>
            <description>While taking liothyronine</description>
          </group>
        </group_list>
        <measure>
          <title>TSH Area Under the Curve</title>
          <description>TSH area under the curve within 60 minutes of TRH stimulation when TSH is at goal</description>
          <units>μIU*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.8" spread="137.3"/>
                    <measurement group_id="O2" value="266.2" spread="140.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TSH Max</title>
        <description>The maximum concentration of TSH after TRH stimulation when TSH is at goal</description>
        <time_frame>Between 0 and 180 min after TRH stimulation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine</title>
            <description>While taking levothyroxine</description>
          </group>
          <group group_id="O2">
            <title>Liothyronine</title>
            <description>While taking liothyronine</description>
          </group>
        </group_list>
        <measure>
          <title>TSH Max</title>
          <description>The maximum concentration of TSH after TRH stimulation when TSH is at goal</description>
          <units>mIU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="3.0"/>
                    <measurement group_id="O2" value="5.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Free T4 Level</title>
        <description>Free thyroxine level when TSH level is at goal on therapy.</description>
        <time_frame>An average of 7 months after initiating therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine</title>
            <description>While taking levothyroxine</description>
          </group>
          <group group_id="O2">
            <title>Liothyronine</title>
            <description>While taking liothyronine</description>
          </group>
        </group_list>
        <measure>
          <title>Free T4 Level</title>
          <description>Free thyroxine level when TSH level is at goal on therapy.</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.11"/>
                    <measurement group_id="O2" value="0.46" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total T3 Level</title>
        <description>Total triiodothyronine level when TSH is at goal on therapy</description>
        <time_frame>An average of 7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levothyroxine</title>
            <description>While taking levothyroxine</description>
          </group>
          <group group_id="O2">
            <title>Liothyronine</title>
            <description>While taking liothyronine</description>
          </group>
        </group_list>
        <measure>
          <title>Total T3 Level</title>
          <description>Total triiodothyronine level when TSH is at goal on therapy</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.24"/>
                    <measurement group_id="O2" value="1.98" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 7 months in each arm</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Levothyroxine</title>
          <description>While taking levothyroxine</description>
        </group>
        <group group_id="E2">
          <title>Liothyronine</title>
          <description>While taking liothyronine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anne Cappola</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2155375359</phone>
      <email>acappola@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

